tiprankstipranks
Xilio Therapeutics Enhances Board with Two New Directors
Company Announcements

Xilio Therapeutics Enhances Board with Two New Directors

Don't Miss our Black Friday Offers:

Xilio Therapeutics (XLO) has provided an update.

Xilio Therapeutics, Inc. has expanded its Board of Directors to nine members, welcoming James Shannon, M.D., as a Class I director, and Aoife Brennan, M.D., as a Class III director, each to serve until their successors are chosen or until an earlier departure. Dr. Shannon joins the Nominating and Corporate Governance Committee, while Dr. Brennan steps onto the Audit Committee. Both directors will be compensated according to the company’s established non-employee director policy and will be covered under the standard indemnification agreement.

Find detailed analytics on XLO stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskXilio Therapeutics Reports Q3 2024 Progress and Financials
TipRanks Auto-Generated NewsdeskXilio Therapeutics Advances Cancer Drug and Financial Outlook
TheFlyXilio Therapeutics announces initial data from Phase 1C trial for XTX101
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App